For the roughly 70–80% of advanced cancer patients who fail to respond to immune-checkpoint inhibitors (ICIs), the question of why has been frustratingly elusive. A large-scale metabolomic analysis now offers a partially answerable version of that question — and points toward a common amino acid as a potential lever for improving outcomes.
Drawing on 4,336 plasma samples from 1,714 patients across five tumor types and 16 cohorts in Europe and North America, researchers applied targeted metabolomics and metagenomics in a multimodal machine-learning framework. Integrating 154 plasma metabolites with clinical variables including age, BMI, and renal function, the model identified five metabolites as key predictors of 12-month progression-free survival. Circulating histidine emerged as a favorable prognostic marker, while long-chain fatty acids and succinate were negatively associated with outcomes. The predictive model achieved an AUC of 0.88 in the training cohort and 0.73 across validation sets, generalizing across seven external cohorts — a meaningful real-world test. Critically, histidine supplementation enhanced antitumor immune activity in mouse models, and patients on histidine-rich diets showed improved progression-free survival, but only when their gut microbiome lacked dysbiotic signatures linked to excess histidine catabolism.
This study is notable for several reasons beyond its scale. The intersection of plasma metabolomics, microbiome profiling, and ICI response is an emerging but fragmented field; this represents one of the most comprehensive multimodal integrations to date. The mechanistic link — that gut microbiome composition influences whether dietary histidine actually reaches the immune system intact — reframes the microbiome's role from a passive biomarker to an active metabolic gatekeeper. The 0.73 AUC in external validation, while imperfect, is clinically meaningful for a notoriously heterogeneous patient population. Key limitations include its observational design for the dietary analyses and the reliance on mouse models for mechanistic validation. Whether histidine supplementation can prospectively improve human ICI outcomes in microbiome-stratified trials remains untested. Still, this is a potentially paradigm-shifting contribution to precision oncology.